Literature DB >> 11826409

Critical flicker frequency for quantification of low-grade hepatic encephalopathy.

Gerald Kircheis1, Matthias Wettstein, Lars Timmermann, Alfons Schnitzler, Dieter Häussinger.   

Abstract

Subclinical hepatic encephalopathy (SHE) is currently diagnosed by psychometric tests or neurophysiologic techniques. In view of its sociomedical relevance, simple and reproducible tests for routine diagnosis are required. This study evaluates critical flicker-frequency thresholds for quantification of low-grade hepatic encephalopathy. A total of 115 patients (92 with cirrhosis, 23 controls) were analyzed for HE severity (mental state, computerized psychometric tests), and the threshold frequencies at which light pulses are perceived as fused (fusion frequency) or flickering light (critical flicker frequency [CFF]). CFF was a highly reproducible parameter with little age, day-time, and training dependency. CFFs in cirrhotic patients without HE (HE 0) were not different from those found in noncirrhotic controls. Significantly lower CFFs were found in cirrhotic patients with subclinical or manifest HE, and the various HE groups separated from each other at a high level of significance (P <.01). By using a CFF cut-off value of 39 Hz, a 100% separation of patients with manifest HE from noncirrhotic controls and HE 0 cirrhotic patients was obtained. SHE patients separated from HE 0 cirrhotic patients with high sensitivity (55%) and specificity (100%). The HE severity-dependent differences were found in both, alcoholic and posthepatitic cirrhosis. Statistically significant correlations (P <.01) were found between CFFs and individual psychometric tests. Aggravation of preexisting HE after transjugular intrahepatic portosystemic stent shunt (TIPS) implantation was accompanied by a corresponding decrease of CFF, whereas improvement of HE increased CFF. In conclusion, CFF is a sensitive, simple, and reliable parameter for quantification of low-grade HE severity in cirrhotic patients and may be useful for the detection and monitoring of SHE.

Entities:  

Mesh:

Year:  2002        PMID: 11826409     DOI: 10.1053/jhep.2002.30957

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  91 in total

1.  Canadian regulations and legal ramifications for hepatic encephalopathy: a descriptive analysis.

Authors:  Henry H Nguyen; Mark G Swain; Philip Wong; Stephen E Congly
Journal:  CMAJ Open       Date:  2018-12-03

Review 2.  Advances in the evaluation and management of minimal hepatic encephalopathy.

Authors:  Jennifer Y Montgomery; Jasmohan S Bajaj
Journal:  Curr Gastroenterol Rep       Date:  2011-02

3.  The Treatment of Patients With Hepatic Encephalopathy: Review of the Latest Data from EASL 2010.

Authors:  Kevin D Mullen
Journal:  Gastroenterol Hepatol (N Y)       Date:  2010-07

4.  Diagnosis and prognostic significance of minimal hepatic encephalopathy in patients with cirrhosis of liver.

Authors:  Radha K Dhiman; Roshan Kurmi; Kiran K Thumburu; Sunil H Venkataramarao; Ritesh Agarwal; Ajay Duseja; Yogesh Chawla
Journal:  Dig Dis Sci       Date:  2010-05-28       Impact factor: 3.199

5.  Role of Magnetic Resonance in Understanding the Pathogenesis of Hepatic Encephalopathy.

Authors:  A Huda; R K Gupta; N Rajakumar; M A Thomas
Journal:  Magn Reson Insights       Date:  2008

Review 6.  Characteristics of minimal hepatic encephalopathy.

Authors:  Piero Amodio; Sara Montagnese; Angelo Gatta; Marsha Y Morgan
Journal:  Metab Brain Dis       Date:  2004-12       Impact factor: 3.584

Review 7.  Neural synchronization in hepatic encephalopathy.

Authors:  Lars Timmermann; Markus Butz; Joachim Gross; Gerald Kircheis; Dieter Häussinger; Alfons Schnitzler
Journal:  Metab Brain Dis       Date:  2005-12       Impact factor: 3.584

8.  Cyclic GMP in blood and minimal hepatic encephalopathy: fine-tuning of the diagnosis.

Authors:  Jan Albrecht
Journal:  J Mol Med (Berl)       Date:  2007-02-02       Impact factor: 4.599

Review 9.  Portal hypertension--old problem, new therapeutic solutions.

Authors:  Markus Peck-Radosavljevic
Journal:  Wien Med Wochenschr       Date:  2006-07

Review 10.  New technologies - new insights into the pathogenesis of hepatic encephalopathy.

Authors:  Luisa Baker; Bernard Lanz; Fausto Andreola; Javier Ampuero; Anisha Wijeyesekera; Elaine Holmes; Nicolaas Deutz
Journal:  Metab Brain Dis       Date:  2016-09-30       Impact factor: 3.584

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.